The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker.

IF 3.3 4区医学 Q2 ONCOLOGY

Breast Cancer : Targets and Therapy Pub Date : 2024-07-03 eCollection Date: 2024-01-01 DOI:10.2147/BCTT.S464161

Mehmet Emin Buyukbayram, Zekeriya Hannarici, Yakup Duzkopru, Aykut Turhan, Alperen Akansel Caglar, Pınar Coban Esdur, Mehmet Bilici, Salim Basol Tekin, Doğan Yazılıtaş

{"title":"The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker.","authors":"Mehmet Emin Buyukbayram, Zekeriya Hannarici, Yakup Duzkopru, Aykut Turhan, Alperen Akansel Caglar, Pınar Coban Esdur, Mehmet Bilici, Salim Basol Tekin, Doğan Yazılıtaş","doi":"10.2147/BCTT.S464161","DOIUrl":null,"url":null,"abstract":"Objective: Hormone positive breast cancer is a tumor with high mortality. Combining antihormonal therapy with cyclin dependent kinase 4/6 inhibitors (CDK4/6i) has resulted in longer survival. The effect of inflammatory parameters such as c-reactive protein and c-reactive protein/lymphocyte ratio (CLR) on efficacy and survival in CDK4/6i treatment is unknown. In our study, we aimed to investigate the role of CLR and some parameters in predicting progression-free survival (PFS) with CDK4/6i.Methods: This retrospective cohort study included 78 patients with denovo and recurrent metastatic breast cancer treated with CDK4/6i. Cut off values for the prediction of mortality by various numerical parameter scores were performed by ROC Curve analysis. The effect of clinical variables, inflammatory and histopathological parameters on survival was analyzed by Kaplan-Meier method.Results: Neutrophil/lymphocyte ratio (NLR) and CLR were statistically significant in predicting mortality (p < 0.05). Ki67 and CLR were correlated with PFS. Age and CLR were correlated with OS (p < 0.05). CLR was statistically significant for both PFS (p = 0.022) and OS (p = 0.006).Conclusion: In patients with metastatic hormone-positive breast cancer using CDK4/6i, low CLR and low Ki67 were correlated with longer PFS duration.","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"329-339"},"PeriodicalIF":3.3000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227876/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/BCTT.S464161","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Hormone positive breast cancer is a tumor with high mortality. Combining antihormonal therapy with cyclin dependent kinase 4/6 inhibitors (CDK4/6i) has resulted in longer survival. The effect of inflammatory parameters such as c-reactive protein and c-reactive protein/lymphocyte ratio (CLR) on efficacy and survival in CDK4/6i treatment is unknown. In our study, we aimed to investigate the role of CLR and some parameters in predicting progression-free survival (PFS) with CDK4/6i.

Methods: This retrospective cohort study included 78 patients with denovo and recurrent metastatic breast cancer treated with CDK4/6i. Cut off values for the prediction of mortality by various numerical parameter scores were performed by ROC Curve analysis. The effect of clinical variables, inflammatory and histopathological parameters on survival was analyzed by Kaplan-Meier method.

Results: Neutrophil/lymphocyte ratio (NLR) and CLR were statistically significant in predicting mortality (p < 0.05). Ki67 and CLR were correlated with PFS. Age and CLR were correlated with OS (p < 0.05). CLR was statistically significant for both PFS (p = 0.022) and OS (p = 0.006).

Conclusion: In patients with metastatic hormone-positive breast cancer using CDK4/6i, low CLR and low Ki67 were correlated with longer PFS duration.

查看原文本刊更多论文

C反应蛋白/淋巴细胞比值（CLR）对接受CDK4/6抑制剂治疗的转移性乳腺癌患者PFS的影响：一种新型生物标志物

目的：激素阳性乳腺癌是一种死亡率很高的肿瘤。将抗激素疗法与细胞周期蛋白依赖性激酶 4/6 抑制剂（CDK4/6i）结合使用可延长患者的生存期。c反应蛋白和c反应蛋白/淋巴细胞比值（CLR）等炎症指标对CDK4/6i治疗的疗效和生存期的影响尚不清楚。我们的研究旨在探讨CLR和一些参数在预测CDK4/6i治疗的无进展生存期（PFS）中的作用：这项回顾性队列研究纳入了78名接受CDK4/6i治疗的新发和复发转移性乳腺癌患者。通过ROC曲线分析法得出了各种数字参数评分预测死亡率的临界值。采用 Kaplan-Meier 法分析了临床变量、炎症和组织病理学参数对生存率的影响：结果：中性粒细胞/淋巴细胞比率（NLR）和CLR在预测死亡率方面具有统计学意义（P < 0.05）。Ki67和CLR与PFS相关。年龄和CLR与OS相关（P < 0.05）。CLR对PFS（p = 0.022）和OS（p = 0.006）均有统计学意义：结论：在使用CDK4/6i的激素阳性转移性乳腺癌患者中，低CLR和低Ki67与较长的PFS时间相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊